AGENDIA Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board - Gilde Healthcare

AGENDIA Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board

March 5, 2009

HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Dr. Albert A. (Al) Luderer to its Supervisory Board.

Dr. Luderer has more than 30 years of experience in in vitro medical diagnostics, laboratory medicine and therapeutic development.  Currently, he is the Chief Executive Officer and President of BioTrove, a privately held company using innovative platform technologies to dramatically increase throughput for pharmaceutical screening and genomics research, accelerating drug-discovery decisions and pipeline development.  Dr. Luderer is also the Director of Light Micronics, Inc. and a Scientific Advisory Board member at Washington University’s Department of Biomedical Engineering, St. Louis, MO.

“We are very pleased to welcome Al to our Supervisory Board,” commented Bernhard Sixt, Ph.D., President and Chief Executive Officer of Agendia.  “As we continue to expand our U.S. activities, Al’s extensive experience and track record of success in the diagnostics industry will prove extremely valuable to Agendia’s growth.”

Previously, Dr. Luderer served as Director, President and Chief Executive Officer of Light Sciences Corporation where he spearheaded the company’s combined business, technical and commercial activities. Prior to joining Light Sciences Corporation, Dr. Luderer was President and Chief Operating Officer at bioMerieux, Inc., a world leader in in vitro diagnostics.  From 1987 – 1993, Dr. Luderer was at Boehringer Mannheim Corporation (now Roche) where he was named Vice President of Technology Development and Support. He started his work in the sector at Corning Inc. as a key figure negotiating the joint venture diagnostic company Ciba Corning (now Siemens Healthcare Diagnostics).

Dr. Luderer holds a Bachelor of Arts from Drew University and an M.S. and Ph.D. from Rutgers University where he was a National Science Foundation pre-doctoral fellow.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company’s tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

More news

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025

Gilde Healthcare company CatalYm announces first patient dosed in Phase 2b trial evaluating Visugromab in combination with chemoimmunotherapy as frst-line treatment in Metastatic Non-squamous NSCLC

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company’s anti-GDF-15 antibody visugromab, in combination with standard-of-care...
September 30, 2025